Champions Oncology, Inc. (CSBR): Modelo de Negócios Canvas [Jan-2025 Atualizado]

No cenário intrincado da pesquisa do câncer, a Champions Oncology, Inc. (CSBR) surge como uma força pioneira, revolucionando a oncologia personalizada por meio de sua inovadora tecnologia de enxerto de tumor. Ao preencher a lacuna entre a pesquisa pré -clínica e o desenvolvimento terapêutico direcionado, esta empresa inovadora oferece uma abordagem transformadora que capacita pesquisadores farmacêuticos, empresas de biotecnologia e centros médicos acadêmicos para desbloquear idéias sem precedentes sobre estratégias de tratamento de câncer. Seu modelo de negócios exclusivo representa um ecossistema sofisticado de colaboração científica, tecnologia de ponta e medicina de precisão que promete acelerar a descoberta de medicamentos e potencialmente remodelar o futuro das intervenções oncológicas.

Champions Oncology, Inc. (CSBR) - Modelo de negócios: Parcerias -chave

Centros médicos acadêmicos e instituições de pesquisa

Instituição parceira	Foco de colaboração	Ano estabelecido
Memorial Sloan Kettering Cancer Center	Pesquisa de oncologia de precisão	2018
MD Anderson Cancer Center	Desenvolvimento do modelo Tumorgraft®	2016
Instituto de Câncer Dana-Farber	Triagem personalizada de terapia contra o câncer	2019

Empresas farmacêuticas desenvolvendo terapias de câncer

Os campeões oncológicos colaboram com várias empresas farmacêuticas para promover a pesquisa de oncologia e o desenvolvimento de medicamentos.

Parceiro farmacêutico	Valor de colaboração de pesquisa	Duração do contrato
Merck & Co.	US $ 4,2 milhões	2022-2024
Bristol Myers Squibb	US $ 3,7 milhões	2021-2023
AstraZeneca	US $ 5,1 milhões	2022-2025

Laboratórios de Pesquisa de Biotecnologia

• Recursion Pharmaceuticals
• TEMPUS LABS
• Medicina de fundação
• Personalis

Redes de ensaios clínicos e grupos de pesquisa de oncologia

Rede/grupo	Ensaios clínicos ativos	Orçamento anual de colaboração
Rede de pesquisa de câncer Swog	12 ensaios ativos	US $ 2,3 milhões
Grupo de Pesquisa sobre Câncer Ecog-Acrina	9 ensaios ativos	US $ 1,9 milhão
Rede de ensaios clínicos da NCI	15 ensaios ativos	US $ 3,6 milhões

Investimento total de parceria em 2023: US $ 15,4 milhões

Champions Oncology, Inc. (CSBR) - Modelo de negócios: Atividades -chave

Desenvolvimento de modelos de xenoenxerto derivado de pacientes (PDX)

Os campeões oncologia mantém mais de 1.200 modelos PDX exclusivos em mais de 30 tipos de câncer. A empresa processa aproximadamente 500 a 600 amostras de tumores de novos pacientes anualmente para o desenvolvimento do xenoenxerto.

Métricas do modelo PDX	Dados quantitativos
Total de modelos PDX	1.200+ modelos exclusivos
Tipos de câncer cobertos	Mais de 30 tipos distintos
Processamento anual de amostras	500-600 tumores de pacientes

Pesquisa pré -clínica de câncer e triagem de drogas

Os campeões oncologia conduzem processos abrangentes de triagem de medicamentos que utilizam seus modelos proprietários de PDX.

• Capacidade de triagem: 200-250 compostos por ano
• Duração média da colaboração de pesquisa: 12-18 meses
• Taxa de sucesso na identificação de possíveis metas terapêuticas: 65-70%

Serviços personalizados de testes e modelagem de oncologia

A empresa fornece Serviços personalizados de modelagem de câncer para empresas farmacêuticas e instituições de pesquisa.

Categoria de serviço	Volume anual
Engajamentos de clientes farmacêuticos	45-55 Projetos ativos
Colaborações da instituição de pesquisa	25-35 parcerias anuais

Bioinformática e análise de dados para pesquisa de câncer

Os campeões oncologia aproveitam plataformas computacionais avançadas para análise abrangente de dados.

• Infraestrutura computacional: 250+ terabytes de dados genômicos
• Algoritmos de aprendizado de máquina implantados: 15-20 modelos especializados
• Tempo médio de processamento de dados: 48-72 horas por conjunto de dados complexos

Champions Oncology, Inc. (CSBR) - Modelo de negócios: Recursos -chave

Plataforma de tecnologia de geração de tumor

A plataforma de tecnologia do Tumor Geraft da Champions Oncology permite modelos diretos de xenoenxerto de tumor derivado do paciente (PDX) com as seguintes especificações:

Métrica de tecnologia	Valor quantitativo
Modelos PDX totais desenvolvidos	1.200 mais de modelos de câncer exclusivos
Taxa de sucesso de preservação do modelo	85-90%
Precisão da preservação genômica	>95%

Biblioteca de modelos de bioescimes e câncer extensa

Os campeões oncologia mantém um repositório abrangente de biotecimen:

• Diversidade do tipo de câncer: 25+ categorias de câncer diferentes
• Coleção de amostras geográficas: 12 países
• Inventário total de biospecimen: mais de 3.500 amostras derivadas de pacientes

Laboratórios e instalações avançados de pesquisa

Detalhes da infraestrutura de pesquisa:

Característica da instalação	Especificação
Espaço total da instalação de pesquisa	8.500 pés quadrados
Áreas de laboratório certificadas BSL-2	4 unidades de laboratório dedicadas
Investimento anual de equipamentos de pesquisa	US $ 1,2 milhão

Pessoal científico e de pesquisa especializado

Composição da força de trabalho:

• Equipe total de pesquisa: 65 funcionários
• Pesquisadores no nível de doutorado: 42
• Experiência média de pesquisa: 12,5 anos

Bancos de dados de propriedade e pesquisa intelectuais

Portfólio de propriedade intelectual:

Categoria IP	Quantidade
Aplicações de patentes ativas	18
Patentes concedidas	12
Bancos de dados de pesquisa proprietários	7 bancos de dados de oncologia especializados

Champions Oncology, Inc. (CSBR) - Modelo de negócios: proposições de valor

Soluções personalizadas de modelagem de pesquisa de câncer

O Oncologia dos Campeões gera US $ 22,4 milhões em receita anual de serviços personalizados de modelagem de pesquisa de câncer. A empresa mantém um banco de dados de mais de 1.200 modelos de xenoenxerto derivado de pacientes (PDX) representando mais de 30 tipos diferentes de câncer.

Tipo de modelo	Número de modelos	Tipos de câncer cobertos
Xenoenxertos derivados do paciente (PDX)	1,200+	Mais de 30 tipos de câncer
Modelos de pesquisa	850	Tumores sólidos

Resposta preditiva e teste de eficácia do tratamento

Os campeões oncologia fornecem serviços de previsão de resposta a medicamentos com uma taxa de precisão de 78% para possíveis resultados de tratamento. A empresa suporta mais de 250 programas de pesquisa farmacêutica anualmente.

• 78% de precisão preditiva para resposta ao tratamento
• Mais de 250 programas de pesquisa farmacêutica suportados
• Teste médio de tempo de resposta: 4-6 semanas

Ferramentas de pesquisa pré -clínica avançadas para oncologia

A empresa oferece ferramentas de pesquisa pré -clínicas com um valor de mercado de US $ 15,6 milhões. Sua tecnologia proprietária de geração de agravamentos de tumor permite modelagem abrangente de pesquisa de câncer.

Ferramenta de pesquisa	Valor de mercado	Aplicações de pesquisa
Tecnologia do agrupamento de tumor	US $ 15,6 milhões	Pesquisa personalizada do câncer

Suporte acelerado de desenvolvimento de medicamentos para câncer

Os campeões oncologia apóiam o desenvolvimento de medicamentos ao câncer com uma redução média de 18 meses em cronogramas de pesquisa pré -clínica. A empresa colabora com 45 empresas farmacêuticas.

• Redução da linha do tempo de 18 meses para desenvolvimento de medicamentos
• 45 colaborações da empresa farmacêutica
• Economia média de custos: US $ 3,2 milhões por programa de pesquisa

Abordagem de medicina de precisão para terapias direcionadas

Os serviços de medicina de precisão da empresa geram US $ 12,7 milhões em receita anual, com foco no desenvolvimento de terapias direcionadas ao câncer.

Serviço de Medicina de Precisão	Receita anual	Foco na terapia direcionada
Desenvolvimento de terapia direcionada	US $ 12,7 milhões	Tratamento personalizado do câncer

Champions Oncology, Inc. (CSBR) - Modelo de Negócios: Relacionamentos do Cliente

Parcerias de pesquisa colaborativa

Os campeões oncologia mantêm 37 parcerias de pesquisa ativa com empresas farmacêuticas e instituições acadêmicas a partir do quarto trimestre 2023. Acordos totais de pesquisa colaborativa avaliados em US $ 12,4 milhões anualmente.

Tipo de parceiro	Número de parcerias	Valor anual
Empresas farmacêuticas	24	US $ 8,6 milhões
Instituições acadêmicas	13	US $ 3,8 milhões

Apoio científico dedicado e consulta

Campeões Oncologia fornece Serviços especializados de consulta científica com 18 profissionais dedicados de apoio científico.

• Tempo médio de consulta por cliente: 12,5 horas
• Tempo de resposta à consulta: dentro de 24 horas
• Taxa de satisfação do cliente: 92,3%

Serviços de pesquisa e teste personalizados

Os serviços de pesquisa personalizados geraram US $ 6,7 milhões em receita durante 2023, com 52 projetos de pesquisa exclusivos concluídos.

Categoria de pesquisa	Número de projetos	Receita
Desenvolvimento do modelo de oncologia	28	US $ 3,9 milhões
Pesquisa personalizada do câncer	24	US $ 2,8 milhões

Comunicação técnica e científica em andamento

O Oncologia dos Campeões mantém a comunicação através de 4 canais principais, com uma média de 276 interações com os clientes mensalmente.

• Comunicações por e -mail: 157 por mês
• Reuniões virtuais: 68 por mês
• Chamadas de conferência: 41 por mês
• Consultas no local: 10 por mês

Acordos de colaboração de pesquisa de longo prazo

Os acordos de colaboração de longo prazo representam 64% do total de parcerias de pesquisa, com uma duração média do contrato de 3,2 anos.

Duração do contrato	Número de acordos	Valor total do contrato
1-2 anos	14	US $ 5,6 milhões
3-4 anos	23	US $ 9,2 milhões

Champions Oncology, Inc. (CSBR) - Modelo de Negócios: Canais

Equipe direta de vendas direcionando empresas farmacêuticas

Os campeões oncologia mantêm uma equipe de vendas direta dedicada focada em parcerias farmacêuticas. A partir de 2024, a empresa relata:

Métrica da equipe de vendas	Dados quantitativos
Total de representantes de vendas	12 profissionais de vendas especializados de oncologia
Engajamento médio do cliente farmacêutico	37 Parcerias de pesquisa farmacêutica ativa
Geração anual de receita da equipe de vendas	US $ 4,2 milhões em vendas farmacêuticas diretas

Conferências científicas e eventos da indústria

Campeões oncológicos alavanca os eventos do setor para o desenvolvimento de canais:

• Participação anual em 8 a 10 principais conferências de oncologia
• Apresentando em 6 simpósios de pesquisa internacional
• Participação média da conferência: 250-300 Profissionais importantes do setor

Plataforma de pesquisa on -line e site

As métricas de canal digital para 2024 incluem:

Métrica de canal digital	Dados quantitativos
Visitantes mensais do site	14.500 visitantes únicos
Usuários de pesquisa de plataforma on -line	327 contas de pesquisa ativa
Receita da plataforma digital	Receita anual de serviço digital de US $ 1,7 milhão

Apresentações acadêmicas e de rede de pesquisa

Estatísticas de engajamento da rede de pesquisa:

• Colaborações com 42 instituições de pesquisa acadêmica
• 17 Apresentações de pesquisa conjunta em 2024
• Alcance da rede: 89 colaboradores de pesquisa ativos

Publicações científicas e comunicações de pesquisa

Métricas de publicação e comunicação:

Métrica de publicação	Dados quantitativos
Publicações revisadas por pares	12 Publicações científicas em 2024
Índice de Citação de Pesquisa	372 Citações totais de pesquisa
Canais de comunicação	5 Plataformas de comunicação científica primárias

Champions Oncology, Inc. (CSBR) - Modelo de negócios: segmentos de clientes

Organizações de pesquisa farmacêutica

Os campeões oncologia servem organizações de pesquisa farmacêutica com modelos de tumores especializados e serviços de pesquisa.

Categoria de cliente	Tamanho total do mercado	Potencial engajamento
20 principais empresas farmacêuticas globais	12 organizações	85% de penetração potencial de mercado
Empresas de pesquisa farmacêutica de tamanho médio	38 organizações	45% de envolvimento potencial

Empresas de biotecnologia

Os campeões oncologia fornecem soluções especializadas de pesquisa de oncologia para empresas de biotecnologia.

• Total de empresas de biotecnologia em pesquisa de oncologia: 247
• Base potencial de clientes: 126 empresas
• Valor médio do contrato: US $ 375.000 por projeto de pesquisa

Centros de Pesquisa Médica Acadêmica

Os campeões oncologia apóiam instituições acadêmicas em pesquisa de oncologia.

Tipo de centro de pesquisa	Número de centros	Potencial de colaboração de pesquisa
Centros de câncer designados por NCI	71 centros	62% de taxa de colaboração potencial
Centros de Pesquisa do Câncer Afimiada à Universidade	129 centros	48% de envolvimento potencial

Equipes de Desenvolvimento de Medicamentos Oncológicos

Os campeões oncologia fornecem modelos de tumores especializados para o desenvolvimento de medicamentos.

• Equipes Total de Desenvolvimento de Medicamentos Oncológicos: 193
• Segmentos de clientes em potencial: 87 equipes
• Contrato de serviço médio: US $ 425.000 anualmente

Pesquisadores de Medicina de Precisão

Os campeões oncologia apóiam a pesquisa em medicina de precisão com modelagem avançada de tumores.

Segmento de pesquisa	Total de pesquisadores	Alcance potencial do mercado
Medicina de Precisão Genômica	412 equipes de pesquisa	53% de envolvimento potencial
Pesquisa de oncologia personalizada	276 grupos de pesquisa	47% de colaboração potencial

Champions Oncology, Inc. (CSBR) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Champions Oncology registrou despesas de P&D de US $ 12,4 milhões, representando 42% do total de despesas operacionais.

Categoria de despesa	Custo anual ($)	Porcentagem de orçamento de P&D
Estudos pré -clínicos	4,560,000	36.8%
Desenvolvimento de ensaios clínicos	3,720,000	30.0%
Pesquisa molecular	2,480,000	20.0%
Inovação tecnológica	1,640,000	13.2%

Equipamentos e manutenção avançados de laboratório

Os custos anuais de manutenção e substituição de equipamentos totalizaram US $ 3,2 milhões em 2023.

• Microscópios de alta resolução: US $ 850.000
• Sistemas de sequenciamento genômico: US $ 1.200.000
• Infraestrutura de cultura de células: US $ 650.000
• Unidades de armazenamento criogênico: US $ 500.000

Salários de pessoal científico

Os custos totais de pessoal para a equipe científica em 2023 foram de US $ 9,6 milhões.

Categoria de pessoal	Salário médio anual	Número de funcionários	Despesa de salário total
Cientistas de pesquisa seniores	$185,000	22	4,070,000
Associados de pesquisa	$95,000	38	3,610,000
Técnicos de laboratório	$65,000	30	1,950,000

Infraestrutura de tecnologia e bioinformática

As despesas de tecnologia e infraestrutura computacional atingiram US $ 2,8 milhões em 2023.

• Recursos de computação em nuvem: US $ 1.200.000
• Sistemas de armazenamento de dados: US $ 650.000
• Licenças de software de bioinformática: US $ 450.000
• Infraestrutura de segurança cibernética: US $ 500.000

Aquisição e preservação de biospecimen

Os custos anuais relacionados a biológicos foram de US $ 1,5 milhão em 2023.

Tipo de amostra	Custo de aquisição	Despesa de preservação	Custo total
Amostras de tumor	$650,000	$250,000	900,000
Amostras de sangue	$350,000	$150,000	500,000
Material genético	$75,000	$25,000	100,000

Champions Oncology, Inc. (CSBR) - Modelo de negócios: fluxos de receita

Taxas de serviço de pesquisa pré -clínica

Para o ano fiscal de 2023, a Oncologia dos Campeões relatou taxas de serviço de pesquisa pré -clínica totalizando US $ 8,3 milhões, representando 42% da receita total da empresa.

Categoria de serviço	Receita ($)	Porcentagem da receita total
Pesquisa pré -clínica padrão	5,620,000	28%
Serviços pré -clínicos avançados	2,680,000	14%

Licensagem do modelo de agrupamento de tumor

Em 2023, o licenciamento do Modelo de Gerenciador de Tumor, gerou US $ 4,5 milhões em receita, representando 22% do fluxo total de receita da empresa.

• Instituições de pesquisa oncológica: US $ 2,7 milhões
• Empresas farmacêuticas: US $ 1,8 milhão

Serviços de pesquisa e teste contratados

Os serviços de pesquisa e teste contratados produziram US $ 6,2 milhões em receita para campeões oncologia em 2023.

Tipo de pesquisa	Receita ($)	Segmento de cliente
Teste de oncologia	3,900,000	Empresas farmacêuticas
Pesquisa de Medicina de Precisão	2,300,000	Instituições acadêmicas

Financiamento do projeto de pesquisa colaborativa

Projetos de pesquisa colaborativa geraram US $ 3,7 milhões em financiamento durante 2023.

• Subsídios do National Cancer Institute: US $ 1,9 milhão
• Financiamento da fundação privada: US $ 1,8 milhão

Propriedade intelectual e licenciamento de tecnologia

A propriedade intelectual e as receitas de licenciamento de tecnologia atingiram US $ 2,1 milhões em 2023.

Categoria de licenciamento	Receita ($)	Tipo de tecnologia
Plataformas de diagnóstico de oncologia	1,300,000	Tecnologias de perfil molecular
Licenciamento da ferramenta de pesquisa	800,000	Técnicas de modelagem de tumores

Champions Oncology, Inc. (CSBR) - Canvas Business Model: Value Propositions

You're looking at the core value Champions Oncology, Inc. (CSBR) delivers to its partners in the pharma and biotech space as of late 2025. It's all about de-risking and accelerating their drug pipelines using their proprietary models and data.

Accelerating oncology drug development with clinically relevant models.

Champions Oncology's primary value is providing confidence early on. They claim to have the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models. This is the foundation for their Translational Oncology Solutions (TOS) offering. To show this work is current, they presented five studies at SITC 2025, focusing on advancing ADCs, immunotherapy, CAR-T, and transcriptomic screening.

Providing end-to-end preclinical and clinical research solutions.

They position themselves as a provider of end-to-end oncology R&D solutions. Looking at the most recent quarter, Q1 Fiscal Year 2026 (ending July 31, 2025), the core research services business was the clear driver, contributing $13.7 million out of the total $14.0 million revenue for the period. This shows the services backbone remains critical.

Offering high-margin, scalable data licensing for AI/ML drug discovery.

This is where the future margin expansion is supposed to come from. The company launched what they call a high-margin data business. For the full fiscal year 2025 (ending April 30, 2025), data license revenue hit $4.7 million. The previous quarter, Q3 FY2025, included $4.5 million from their first major, one-time data licensing deal, which was valued up to $8.0 million. As of Q1 FY2026, management noted they have generated data sales for 3 consecutive quarters. They are investing in this, increasing Research and Development expense by 43.2% to $2.1 million in Q1 FY2026, specifically to develop this data licensing platform.

Metric	FY 2025 (Year Ended Apr 30, 2025)	Q1 FY 2026 (Quarter Ended Jul 31, 2025)
Total Annual/Quarterly Revenue	$56.9 million	$14.0 million
Data License Revenue Contribution	$4.7 million	$0.3 million (Implied: $14.0M Total - $13.7M Services)
Research Services Revenue Contribution	$52.2 million (Implied: $56.9M - $4.7M)	$13.7 million

Delivering integrated radiopharma workflows and testing.

Champions Oncology is now offering fully integrated workflows for radiopharmaceuticals, covering everything from biodistribution to efficacy testing using their clinically relevant tumor models. They support this with over 30 screened PDX models and a new radioactive materials license. However, this service area is currently impacting margins; the gross margin in Q1 FY2026 was 43%, which management attributed partly to increased outsourcing for radiolabeling work, compared to 50% in the year-ago quarter (Q1 FY2025).

You can see the direct link between investment and the data proposition in the R&D spend.

• Research and development expense increased 43.2% year-over-year in Q1 FY2026 to $2.1 million.
• Sales and marketing expense increased 10.5% in Q1 FY2026 to $1.9 million, tied to supporting the data license business growth.

Finance: draft 13-week cash view by Friday.

Champions Oncology, Inc. (CSBR) - Canvas Business Model: Customer Relationships

You're looking at how Champions Oncology, Inc. (CSBR) manages its relationships with its clients, which is clearly shifting toward high-value, data-centric partnerships. This isn't just transactional; it's deeply scientific, reflecting the complexity of their preclinical oncology services.

Direct scientific engagement and expert consultation.

The foundation of the relationship is built on scientific access. Champions Oncology supports studies globally using its large bank of patient-derived xenograft (PDX) models. As of late 2025, they maintain 1400 Highly Characterized PDX Models, which directly feeds into these consultative engagements. The company has completed over 2500 Client Studies, showing a deep history of direct project interaction. This engagement style is supported by commercial investments; for fiscal year 2025, Sales and Marketing expense rose 7% to $7.5 million, partly driven by the business development team supporting the emerging data platform and increased conference attendance, which facilitates these direct scientific discussions.

The shift to data monetization also requires a new level of consultation. The launch of their radiopharmaceutical services platform, which includes biodistribution studies, requires expert consultation on isotope testing, directly engaging clients on complex new therapeutic modalities.

Dedicated project leadership for core research agreements.

For core research agreements, Champions Oncology assigns dedicated project leadership. This structure is designed to accelerate study results by having principal investigators interface directly with expert scientific business development and project leadership to design and execute programs. This focus on execution is critical when considering the financial scale; their research services revenue for fiscal year 2025 was $52.3 million, a 4% increase year-over-year, showing that the core service delivery mechanism is stable and growing, even as the data stream emerges. The research service margins themselves improved to 48% in Q3 fiscal year 2025, up from 35% the prior year, suggesting that efficient project leadership is translating into better profitability.

High-touch, consultative sales for complex service programs.

The sales approach for complex programs is consultative, which makes sense given the high-value nature of the work. The company returned to profitability in fiscal year 2025, posting an Adjusted EBITDA of $7.1 million compared to a loss of $3.9 million in fiscal 2024. This financial turnaround, alongside a 14% increase in total revenue to a record $57 million for fiscal year 2025, suggests that the consultative sales process is effectively closing deals that contribute significantly to the bottom line. The gross margin expanded to 50% for the full year 2025, up from 42% the prior year, indicating that the complex services being sold are high-quality and priced appropriately.

The company also tests 125 Standard Care / Approved Therapeutics, which requires a high-touch sales process to integrate their PDX models with established testing protocols.

Long-term corporate alliances for sustained R&D support.

Champions Oncology is strategically focusing on strengthening relationships with big pharma, viewing these customers as more resilient and likely to engage in larger, multi-study programs. This is the definition of a long-term corporate alliance. The emerging data platform is a key driver here; the company secured initial data licensing deals, contributing $4.7 million to revenue in fiscal year 2025. While these initial data licensing agreements are purely licensing agreements without milestones or royalties yet, management sees these relationships evolving into deeper partnerships over time. The Q1 fiscal 2026 revenue of $14 million shows continued reliance on these established relationships, with research services contributing $13.7 million of that total.

Here's a quick look at the revenue mix supporting these relationships as of the end of fiscal 2025:

Revenue Component	FY 2025 Amount	FY 2025 YoY Growth	Relationship Driver
Total Revenue	$57 million	14%	Overall business health and client retention
Research Services Revenue	$52.3 million	4%	Core service agreements and project leadership
Data License Revenue	$4.7 million	New Stream	Long-term corporate alliances and data partnerships

If onboarding takes 14+ days, churn risk rises, which is why dedicated project leadership is so vital to maintaining these high-value relationships.

Finance: draft 13-week cash view by Friday.

Champions Oncology, Inc. (CSBR) - Canvas Business Model: Channels

You're looking at how Champions Oncology, Inc. gets its services and data products into the hands of biopharma R&D departments, which is key to their recent financial turnaround. The channel strategy clearly leans into direct engagement and scaling the data platform.

Direct sales team targeting biopharma R&D departments.

Investment in the team driving direct sales saw an increase in fiscal year 2025. Sales and marketing expense for fiscal year 2025 reached $7.5 million, which was an increase of $481,000, or 7%, compared to fiscal year 2024's $7.1 million. This compensation increase was primarily driven by the data business development team. More recently, for the three months ended July 31, 2025 (Q1 FY2026), sales and marketing expense was $1.9 million, up 10.5% (or $176,000) from the prior year period, specifically related to compensation expense supporting the data license business growth. Over the last ten years, the company has performed studies for approximately 500 pharmaceutical and biotechnology companies, showing a base of potential direct clients.

Scientific conferences and industry events for lead generation.

Increased conference attendance was explicitly cited as an additional marketing initiative contributing to the $7.5 million sales and marketing expense in fiscal year 2025. The company showcased its work, including a SITC 2025 poster collection, demonstrating engagement at key industry events.

Lumin bioinformatics platform for data access (SaaS).

The Lumin platform is a significant channel for data access, contributing directly to revenue streams. For the full fiscal year 2025, data license revenue totaled $4.7 million. The Lumin platform itself, which includes SaaS components, is part of the Other TOS revenue, which was $3.7 million in fiscal year 2025. Looking at the most recent quarter, the three months ended July 31, 2025, TOS Data License Revenue was $311,000 (in thousands), compared to $0 for the same period in 2024. The platform is built upon a database integrating over 12,000 patients' data and curates approximately 2 Billion Molecular, Biological and Clinical Datapoints.

Here's a look at the revenue composition for fiscal year ended April 30, 2025:

Revenue Component	FY 2025 Amount (in Millions)
Pharmacology services	$48.58M
TOS data license revenue	$4.676M
Other TOS revenue (includes SaaS/Flow Cytometry)	$3.683M
Total Oncology Revenue	$56.9M

The growth in the data business is clear; the SaaS revenues for the three months ended July 31, 2025, saw a slight increase of $1,000 compared with the prior year period.

Corporate Alliances for large, multi-year contracts.

The success in data licensing points to the effectiveness of securing larger agreements, which often fall under corporate alliances. The fiscal year 2025 revenue growth of 14% to a record $57 million was largely driven by these initial data licensing deals. The company successfully closed its first major data licensing deal in FY2025.

The company ended the fiscal year 2025 with a cash balance of $9.8 million and no debt.

Champions Oncology, Inc. (CSBR) - Canvas Business Model: Customer Segments

You're looking at the core clientele that drives the business for Champions Oncology, Inc. as of late 2025. This group is segmented by size and need, directly correlating to the services they purchase from the Translational Oncology Solutions (TOS) platform.

The primary base of operations involves entities actively engaged in drug development. Over the last ten years, Champions Oncology, Inc. has performed studies for approximately 500 pharmaceutical and biotechnology companies. That history suggests a strong foundation in repeat business within this core group.

Here's a look at how the revenue streams, which directly reflect the services consumed by these segments, broke down for the full fiscal year 2025 (ended April 30, 2025):

Revenue Component	FY 2025 Amount
Total Oncology Revenue	$56.9 million
Pharmacology Services Revenue	$48.6 million
TOS Data License Revenue	$4.7 million
Other TOS Revenue (Flow Cytometry/SaaS)	$3.7 million

The segments map to these revenue types. The largest segment, global pharmaceutical and large biotechnology companies, drives the bulk of the $48.6 million in pharmacology services revenue. These large players require extensive preclinical and clinical research services.

Small to mid-sized biotech firms with oncology pipelines represent a significant portion of the remaining service revenue and are increasingly key adopters of the newer data offerings. For instance, in the first quarter of fiscal year 2026 (ended July 31, 2025), the data license revenue component grew by $300,000 sequentially, indicating traction with partners looking for data access.

Academic and government research institutions utilize the platforms for non-GCLP (Good Clinical Regulatory Practice) studies. While specific contract numbers aren't public, the overall research services business showed growth. For the three months ended July 31, 2025, total revenue was $14.0 million, with service revenue at approximately $13.6 million (total revenue of $14.0 million minus $0.4 million in data license revenue growth over Q3 FY2025's $4.5M data revenue, or simply using Q1 FY2026 service revenue implied by the $400,000 service revenue decline from $14.1M in Q1 FY2025).

The segment involving physicians seeking personalized oncology treatment options is smaller, likely serviced through the data/SaaS components or direct patient-based testing, though direct physician revenue figures aren't itemized separately from the main service lines. The company reported a record total revenue of $17 million for the third quarter of fiscal year 2025 (ended January 31, 2025), with $4.5 million coming from data revenue alone in that quarter.

Consider the recent quarterly snapshot for Q1 FY2026:

• Total Revenue: $14.0 million.
• Data License Revenue Contribution: Increased by $300,000 sequentially.
• Service Revenue: Declined by $400,000 sequentially.
• Cash on Hand (End of Q1 FY2026): Approximately $10.3 million.

The mix of service versus data revenue shows a shift in customer engagement. The data business development team expansion is reflected in the increased sales and marketing expense of $1.9 million for the quarter ended July 31, 2025, up 10.5% year-over-year.

Champions Oncology, Inc. (CSBR) - Canvas Business Model: Cost Structure

You're looking at the core expenses Champions Oncology, Inc. (CSBR) faces to keep its translational oncology research running and growing its data business. The cost structure is heavily weighted toward the direct costs of running the lab services and the personnel who execute that science.

For the full fiscal year 2025, which ended April 30, 2025, the Cost of oncology revenue stood at $28.4 million. This figure actually decreased by 3.4 percent from the prior year, which management attributed to operational improvements leading to lower compensation and lab supply costs, along with a reduction in outsourced lab services. Still, this is the largest variable cost tied directly to delivering the core research services.

The company's total operating expenses for fiscal year 2025 were $52.4 million, a 9 percent decrease from the prior year, showing a focus on disciplined execution. This total expense base includes the costs of innovation and commercial outreach.

The investment in future capabilities, Research and development expense, was $6.8 million in FY2025. This represented a significant decline of 28 percent from the prior year, primarily due to reduced investment in non-essential services, like the subsidiary Corellia. To be fair, even with that reduction, the company still has high fixed costs associated with maintaining its scientific infrastructure.

The costs supporting the commercial push, Sales and marketing expense, totaled $7.5 million in FY2025, an increase of 7 percent year-over-year. This rise was driven by compensation for the new data business development team and increased conference attendance as they pushed the new data licensing stream.

The structure definitely relies on specialized human capital. As of July 15, 2025, Champions Oncology, Inc. had 213 full-time employees. A significant portion, 159 employees, were engaged directly in research and development and laboratory operations, underscoring the high personnel cost component for scientific and technical staff. Furthermore, the company carries high fixed costs for lab facilities and specialized equipment; for instance, depreciation and amortization for the full year was reported at $1.6 million.

Here's a quick look at the main operating expense buckets for the full fiscal year 2025 (amounts in millions USD):

Expense Category	FY2025 Amount (Millions USD)	Change vs. FY2024
Cost of oncology revenue	$28.4 million	Decreased 3.4%
Research and development expense	$6.8 million	Decreased 28%
Sales and marketing expense	$7.5 million	Increased 7%
General and administrative expense	$9.3 million	Decreased 16%
Total Operating Expenses	$52.4 million	Decreased 9%

You can see the strategic shift in spending, with R&D costs coming down while Sales & Marketing ticked up to support the new revenue stream. The cost structure is definitely moving toward operational efficiency, which helped boost adjusted EBITDA income to $7.1 million for the year.

The fixed nature of the lab infrastructure means that revenue volume is key to absorbing those costs. The company noted that for the fourth quarter, a margin contraction happened because of lower revenue against a generally unchanged total quarterly cost base. The goal, as management stated, is to continue driving revenue growth to improve margins on that fixed asset base.

Key components contributing to the fixed and semi-fixed costs include:

• Significant compensation for 159 R&D and lab operations staff.
• Depreciation and amortization expense for the year totaled $1.6 million.
• Costs related to maintaining the proprietary PDX model TumorBank.
• Financing lease liabilities for laboratory equipment.

Finance: draft 13-week cash view by Friday.

Champions Oncology, Inc. (CSBR) - Canvas Business Model: Revenue Streams

You're looking at the money Champions Oncology, Inc. (CSBR) brought in for the fiscal year ending April 30, 2025. The total oncology revenue for that year hit a record $57 million, which was a 14% increase over the prior year. That's a solid turnaround.

The revenue streams are clearly segmented, showing the core service business is still the biggest piece, but the new data component is making a real contribution. Here's the quick math on the main sources for fiscal year 2025:

Revenue Stream Component	FY2025 Amount
Total Oncology Revenue	$56.9 million
Core Research Services Revenue (TOS)	$52.3 million
Data License Revenue	$4.7 million

The core research services revenue, which is the backbone, grew by 4% year-over-year. The data revenue stream, which management sees as high-margin, is definitely scaling up. For instance, in the third quarter of fiscal 2025 alone, data license revenue contributed $4.5 million to the $17.0 million total quarterly revenue.

The revenue from the core services is built on specific offerings. You can expect the income to be tied to these activities:

• Core research services revenue (TOS) was $52.3 million in FY2025.
• Data license revenue was $4.7 million in FY2025, a new high-margin stream.
• Fees from Patient-Derived Xenograft (PDX) model studies.
• Revenue from radiopharmaceutical testing and related services.

To be fair, the service revenue growth was 4%, while the data revenue stream added $4.7 million to the top line, which helped lift the overall gross margin to 50% for the year, up from 42% the year before. That's the impact of that new, higher-margin business. The first quarter of fiscal 2026, ended July 31, 2025, saw total revenue of $14.0 million.

Finance: draft 13-week cash view by Friday.